Sagimet Biosciences Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
SGMT$10.89+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity (unaudited)
CONDENSED STATEMENTS OF
STOCKHOLDERS’ EQUITY
(in thousands, except share amounts)
| · · · · · · · · · · · · · · · · · · · · · · · · · | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · · · · · · · Accumulated · · · | |||||||||||||||||||
| · · Series A · · · Series B · · Additional · · · · · Other · · Total | |||||||||||||||||||
| · · Common Stock · Common Stock · · Paid-in · · Accumulated · · Comprehensive · · Stockholders’ | |||||||||||||||||||
| · Shares · Amount · Shares · Amount · Capital · Deficit · Income (Loss) · Equity | |||||||||||||||||||
| Balance at January 1, 2025 | | | 30,674,855 | | $3 | | | 1,520,490 | | $— | | $450,883 | | $(295,311) | | $230 | | $155,805 | |
| Stock-based compensation expense | | — | | — | | | — | | — | | 1,472 | | — | | — | | 1,472 | ||
| Unrealized loss on marketable securities | | — | | — | | | — | | — | | — | | — | | (109) | | (109) | ||
| Net loss | | — | | — | | | — | | — | | — | | | (18,176) | | — | | (18,176) | |
| Balance at March 31, 2025 | | 30,674,855 | | $3 | | | 1,520,490 | | $— | | $452,355 | | $(313,487) | | $121 | | $138,992 | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · · · · · · · Accumulated · · · | |||||||||||||||||||||||||
| · · Series A · · · Series B · · Additional · · · · · Other · · Total | |||||||||||||||||||||||||
| · · Common Stock · Common Stock · · Paid-in · · Accumulated · · Comprehensive · · Stockholders’ | |||||||||||||||||||||||||
| · · Shares · Amount · Shares · Amount · Capital · Deficit · Income (Loss) · Equity | |||||||||||||||||||||||||
| Balance at January 1, 2024 | | | 21,375,402 | | $2 | | | 1,520,490 | | $— | | $340,777 | | $(249,744) | | $30 | | $91,065 | |||||||
| Sale of Series A common stock, net of issuance costs of $7,796 | | | 9,000,000 | | | 1 | | | | — | | | — | | | 104,731 | | | — | | | — | | | 104,732 |
| Issuance of Series A common stock upon exercise of stock options | | | 17,995 | | | — | | | | — | | | — | | | 114 | | | — | | | — | | | 114 |
| Stock-based compensation expense | | — | | — | | | — | | — | | 759 | | — | | — | | 759 | ||||||||
| Unrealized loss on marketable securities | | — | | — | | | — | | — | | — | | — | | (23) | | (23) | ||||||||
| Net loss | | — | | — | | | — | | — | | — | | (6,629) | | — | | | (6,629) | |||||||
| Balance at March 31, 2024 | | 30,393,397 | | $3 | | | 1,520,490 | | $— | | $446,381 | | $(256,373) | | $7 | | $190,018 | ||||||||
The accompanying notes are an integral part of these unaudited condensed financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.